COVID-19 candidate vaccine LUNAR®-COV19 (ARCT-021): Preclinical studies confirmed the effectiveness.

The pharmaceutical company Arcturus announced today that after a single LUNAR®-COV19 (ARCT-021) vaccination of mice, the mice developed a strong antibody response, with the moderate antibody titration continuing into the 60th day.
after the wild SARS-CoV-2 attack, both 2 sg and 10 sg single dose LUNAR-COV19 can completely protect human ACE2 genetically modified mice from death.
the company believes the study, conducted in collaboration with the Duke-NUS School of Medicine, suggests that LUNAR®-COV19 may be a candidate for COVID-19.
company is currently evaluating LUNAR-COV19 in ® I/II clinical studies.
preclinical studies have shown that an immune response mediated by LUNAR®-COV19 (ARCT-021) produces a strong viral antigen-specific CD8-T lymphocyte response and Th1 primary immune response, and that a single LUNAR®-COV19 vaccination at a very low dose of micrograms can completely protect mice from SARS-CoV-infection and death.
Chivukula, chief operating officer of Arcturus, said: "LUNAR®-COV19 is expected to be an efficient, low-dose, single-dose vaccine.
these beneficial properties can bring significant benefits compared to the more commonly used multi-vaccine dosing options."
.